Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOF), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
News about Orexo AB (ORXOF) centers on its activities as a Swedish pharmaceutical company developing improved pharmaceuticals with proprietary formulation technologies. Coverage often highlights developments in its drug delivery platforms, commercial progress in treatments for opioid use disorder, and collaborations to bring its technologies to broader therapeutic areas.
A key news theme for Orexo is its AmorphOX drug delivery platform. The company has reported preclinical pharmacokinetic in-vivo data where AmorphOX was used to create powder-based intranasal formulations of semaglutide, a GLP‑1 receptor agonist. News articles describe how these intranasal formulations were compared with an oral tablet and a subcutaneous injectable, and how the AmorphOX-based powders achieved higher plasma exposure than the oral tablet at median values while showing lower variability in plasma concentration.
Readers following Orexo’s news can expect updates on research and development milestones, such as studies demonstrating the ability of AmorphOX to formulate large molecules that are well absorbed through mucosal membranes. The company also communicates strategic directions, including its stated plan to prioritize larger molecules like peptides, proteins and vaccines and to seek partnerships that expand and accelerate the use of its intranasal powder-based delivery methods.
In addition, Orexo issues news about its role in providing treatment solutions for opioid use disorder in the US market and about the commercialization of products in other therapeutic areas with partners worldwide. This news page brings together such announcements, allowing investors, healthcare professionals and other observers to follow how the company’s technologies and products evolve over time.
Orexo AB (OTCQX: ORXOY) has announced positive results from a preclinical pharmacokinetic study using its AmorphOX® technology to develop intranasal formulations of semaglutide. The study compared three powder-based intranasal formulations with oral (Rybelsus®) and injectable (Wegovy®) versions.
Two of the AmorphOX powder formulations demonstrated a sevenfold increase in plasma values compared to the oral tablet, with lower variability in plasma concentration. While the intranasal formulations showed lower values than injectable delivery, they offer potential advantages including needle-free administration, no refrigeration requirements, and possibly extended dosing schedules.
The successful formulation of large peptides like semaglutide supports Orexo's updated strategy to focus on larger molecules including peptides, proteins, and vaccines.